Shiff Clive
The W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland 21205, USA.
Clin Microbiol Rev. 2002 Apr;15(2):278-93. doi: 10.1128/CMR.15.2.278-293.2002.
Malaria draws global attention in a cyclic manner, with interest and associated financing waxing and waning according to political and humanitarian concerns. Currently we are on an upswing, which should be carefully developed. Malaria parasites have been eliminated from Europe and North America through the use of residual insecticides and manipulation of environmental and ecological characteristics; however, in many tropical and some temperate areas the incidence of disease is increasing dramatically. Much of this increase results from a breakdown of effective control methods developed and implemented in the 1960s, but it has also occurred because of a lack of trained scientists and control specialists who live and work in the areas of endemic infection. Add to this the widespread resistance to the most effective antimalarial drug, chloroquine, developing resistance to other first-line drugs such as sulfadoxine-pyrimethamine, and resistance of certain vector species of mosquito to some of the previously effective insecticides and we have a crisis situation. Vaccine research has proceeded for over 30 years, but as yet there is no effective product, although research continues in many promising areas. A global strategy for malaria control has been accepted, but there are critics who suggest that the single strategy cannot confront the wide range of conditions in which malaria exists and that reliance on chemotherapy without proper control of drug usage and diagnosis will select for drug resistant parasites, thus exacerbating the problem. An integrated approach to control using vector control strategies based on the biology of the mosquito, the epidemiology of the parasite, and human behavior patterns is needed to prevent continued upsurge in malaria in the endemic areas.
疟疾以周期性方式引起全球关注,其受关注程度及相关资金投入会根据政治和人道主义关切而起伏不定。目前我们正处于上升阶段,对此应谨慎发展。通过使用残留杀虫剂以及控制环境和生态特征,欧洲和北美已消除了疟原虫;然而,在许多热带地区和一些温带地区,疟疾发病率却在急剧上升。发病率上升很大程度上是由于20世纪60年代开发和实施的有效控制方法失效,但这也归因于在疟疾流行地区生活和工作的训练有素的科学家和控制专家短缺。此外,对最有效的抗疟药物氯喹的广泛耐药性、对其他一线药物如磺胺多辛-乙胺嘧啶的耐药性发展,以及某些蚊媒物种对一些先前有效的杀虫剂产生耐药性,我们面临着危机局面。疫苗研究已进行了30多年,但目前尚无有效产品,尽管许多有前景的领域仍在继续研究。疟疾控制的全球战略已被接受,但有批评者认为,单一战略无法应对疟疾存在的广泛条件,且在未适当控制药物使用和诊断的情况下依赖化疗会导致产生耐药寄生虫,从而加剧问题。需要采用基于蚊子生物学、寄生虫流行病学和人类行为模式的病媒控制策略的综合控制方法,以防止疟疾流行地区的疟疾持续激增。